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Abstract
Purpose We designed a phase I/II trial of intraperitoneal
(IP) docetaxel plus S-1 to determine the maximum toler-
ated dose (MTD) and recommended dose (RD) and to
evaluate its efficacy and safety in gastric cancer patients
with peritoneal carcinomatosis (PC).
Methods Patients with PC confirmed by laparoscopy or
laparotomy received IP docetaxel on days 1 and 15 and S-1
(80 mg/m2) on days 1–14 every 4 weeks.
Results In the phase I part (n = 12), each cohort received
escalating doses of docetaxel (35–50 mg/m2); the MTD
was determined to be 50 mg/m2 and the RD was deter-
mined to be 45 mg/m2. Dose-limiting toxicities included
grade 3 febrile neutropenia and grade 3 diarrhea. In the
phase II part (n = 27), the median number of courses was 4
(range 2–11). The 1-year overall survival (OS) rate was
70 % (95 % confidence interval 53–87 %). The overall
response rate was 22 % and peritoneal cytology turned
negative in 18 of 22 (81 %) patients. The most frequent
grade 3/4 toxicities included anorexia (19 %), neutropenia
(7 %), and leukopenia (7 %).
Conclusion IP docetaxel plus S-1 is active and safety in
gastric cancer patients with PC.
Keywords Intraperitoneal chemotherapy  Docetaxel 
S-1  Gastric cancer  Peritoneal carcinomatosis
Introduction
Gastric cancer is one of the major causes of cancer death
worldwide; however, recent advances in systemic chemo-
therapy regimens using combinations of novel anti-neo-
plastic agents have shown encouraging tumor response
rates and survival for patients with unresectable or meta-
static gastric cancer.
In patients with positive peritoneal cytology and no
macroscopic peritoneal tumors, radical surgery followed by
postoperative S-1 showed good results with a median
survival time (MST) of 705 days and 2-year survival rate
of 47 % [1]. But the prognosis of patients with macro-
scopic peritoneal carcinomatosis (PC), which is responsible
for about 60 % of all the deaths from gastric cancer [2, 3],
is extremely poor with MST of 3–6 months [4, 5].
As the reason for this, only limited amounts of drugs
reach the peritoneal cavity after intravenous administration
due to the peritoneal-blood barrier [6]. So far, aggressive
methods have been tried to treat PC, such as cytoreductive
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surgery (CRS) plus hyperthermic intraperitoneal chemo-
therapy (HIPEC) [7]. A recent phase III study showed that
patients treated with CRS plus HIPEC had superior sur-
vival to those treated with CRS alone, and the MST for
CRS plus HIPEC was 11.0 months [8]. However, because
of the high morbidity and mortality rates, these aggressive
treatments should only be used for highly selected patients.
Thus, neither regimen has been accepted as the standard
chemotherapy for PC, and a new-multidisciplinary
approach for gastric cancer with PC is needed.
The oral anticancer drug S-1 is a fluoropyrimidine
derivative, combining tegafur with two modulators [9]. In
recent phase III studies, S-1 showed response rates of
27–31 % and MST of 10.5–11.4 months [10, 11], and it is
considered to be a pivotal agent for gastric cancer in Japan.
S-1 was also highly effective against gastric PC due to the
higher concentrations of 5-FU and CDHP achieved in
peritoneal tumors than in plasma [12].
Docetaxel, which binds to tubulin, leading to microtu-
bule stabilization, and mitotic arrest [13], has been widely
used in the treatment of gastric cancer with response rates
of 16–24 % when used as a single agent in phase II trials
[14, 15]. Furthermore, docetaxel has high sensitivity
against diffuse-type adenocarcinoma, which is a common
type of peritoneal tumor, and some of these compounds,
when administered intravenously, are transported into the
peritoneal cavity [16, 17]. These findings suggest that
combination therapy using S-1 and intravenous docetaxel
is also one of the candidates for first-line treatment for PC.
Intraperitoneal administration of docetaxel (IP doce-
taxel) was developed to enhance antitumor activity against
PC by maintaining a high concentration of the drug.
Although we previously reported the efficacy and safety of
weekly IP docetaxel monotherapy [18], there have been
few clinical trials using IP docetaxel plus S-1 with accurate
estimation of peritoneal disease. In this study, we con-
ducted a phase I/II study of IP docetaxel plus S-1 to




The patients enrolled in this study had histologically con-
firmed with PC. Before enrollment in the study, PC was
confirmed by either laparoscopy or laparotomy. PC was
classified according to the criteria of the Japanese Research
Society for Gastric Cancer [19] as follows: P1, cancerous
implants to the region directly adjacent to the stomach
peritoneum (cranial to the transverse colon) including the
great omentum; P2, several scattered metastases to the
distant peritoneum and ovarian metastasis alone; and P3,
numerous metastases to the distant peritoneum. Photo-
graphs of peritoneal lesions were taken before and after
treatment to estimate an objective response. Other criteria
for inclusion were: (1) Eastern Cooperative Oncology
Group (ECOG) performance status of 0–2; (2) age ranged
between 20 and 75 years old; (3) adequate bone marrow,
liver, and renal functions as defined by WBC [4,000,
\12,000/mm3, PLT [100,000/mm3, Hb [8.0 g/dl, AST/
ALT \2 times institutional upper limit, total bilirubin
\1.5 mg/dl, creatinine\1.5 mg/dl and creatinine clearance
[60 mL/min; (4) no significant cardiac disease evident on
electrocardiogram; and (5) expected survival period [3
months.
The exclusion criteria were the following: (1) previous
treatment for gastric cancer; (2) coexistence of another
malignant neoplasm; (3) a history of reactions to drugs; (4)
massive ascites and/or pleural effusion; and (5) brain
metastasis.
This study was approved by the Institutional Review
Boards of each institution, and the procedures were per-
formed in accordance with the Declaration of Helsinki. All
patients provided written informed consent to participation
in the study in accordance with the institutional guidelines.
Treatment schedule
An initial laparoscopy or mini-laparotomy was performed
under general anesthesia in patients with advanced gastric
cancer diagnosed histologically or patients with peritoneal
recurrence diagnosed by imaging.
Palliative surgery for tumor reduction was not carried
out. A peritoneal access port was implanted in the subcu-
taneous space of the lower abdomen, with a catheter placed
in the pelvic cavity.
S-1 was administered orally at a fixed dose of 40 mg/m2
twice daily on days 1–14 every 4 weeks. Docetaxel was
administered with 1,000 ml of 0.9 % sodium chloride
solution via the implanted peritoneal access port for 2 h
after standard premedication on days 1 and 15. Each cycle
was performed every 4 weeks.
Clinical trials of IP docetaxel as a single agent revealed
the RD of 45 mg/m2 weekly on days 1, 8, and 15 during the
4-week cycle for advanced gastric cancer patients [18]. In
the present study, we planned combination chemotherapy
using IP docetaxel plus S-1, which was thought to be more
toxic than IP docetaxel monotherapy. Therefore, during
phase I, the initial dose of docetaxel was 35 mg/m2 (Level
1) and the dose was escalated by 5 mg/m2 for each dose
level up to 50 mg/m2 (Level 4).
The DLTs were defined as follows: (1) grade 4 hema-
tological toxicity, (2) transfusion of platelets for throm-
bocytopenia, (3) grade 3 neutropenia with infection or fever
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[38.0 C, (4) grade 3 or greater non-hematological tox-
icity with the exception of loss of appetite, nausea, and
vomiting, and (5) treatment delay of more than 2 weeks
following the last administration of docetaxel.
At least three patients were to be started at dose level 1:
(1) the dose was defined as the maximum tolerated dose
(MTD) when all patients developed DLT; (2) when one or
two of three patients developed DLT, three other patients
were enrolled, (3) when more than three of six patients
developed DLT, the dose was defined as MTD; (4) when
fewer than two of six patients developed DLT, the dose
was increased to the next level. Assessment of DLT was
conducted during the first two treatment cycles.
Phase II was performed using the RD determined during
phase I. The treatment course was repeated until observa-
tion of unacceptable toxicity or disease progression.
After 2 treatment cycles, either second laparoscopy or
laparotomy was scheduled to evaluate the effect of the
treatment on PC. Surgical resection was performed for
macroscopically curative operation according to second
laparoscopic finding. Treatment after disease progression
or surgery was at the physician’s discretion.
Evaluation of tumor response
Peritoneal carcinomatosis is considered to be a non-
evaluable lesion because it is difficult to detect PC by
conventional radiological examinations. In this study, we
developed new response criteria for treatment against PC:
Complete response (CR), no detection of cancer cells in the
peritoneal cytology and disappearance of all peritoneal
tumors macroscopically and histologically; Partial response
(PR), no detection of cancer cells in the peritoneum
cytology and at least a 50 % decrease in the sum of the
longest diameter of a peritoneal tumor using photographs
of peritoneal lesions taken to confirm an objective response
before and after treatment; Stable disease (SD), an insuf-
ficient decrease in the sum of the longest diameter of
peritoneal tumor using photographs of the peritoneal
lesions; Progressive disease (PD), exacerbation of a peri-
toneal tumor or the appearance of new peritoneal tumor
lesions.
Peritoneal tumor response was evaluated using intra-
peritoneal photographs which were taken in the first and
second laparoscopy according to the aforesaid new
response criteria by the physician’s discretion. If peritoneal
deposits were found, biopsy was performed to distinguish
fibrosis from metastatic nodule.
Measurable lesions of the tumor response were evalu-
ated after 2 treatment cycles using CT scans according to
the Response Evaluation Criteria in Solid Tumors (RE-
CIST) ver. 1.0.
Phase II study: statistical planning and analysis
The primary endpoint for the phase II part of the study was
the 1-year overall survival (OS) rate, and the secondary
endpoints were the overall response rate (ORR), efficacy
against malignant ascites, and safety.
The required number of patients was calculated accord-
ing to the Southwest Oncology Group One Arm Survival
program [20]. Recent studies in advanced or metastatic
gastric cancer including patients with PC showed a 1-year
OS rate of 50 % [10, 11, 21]. A 1-year OS rate of 70 %
could be expected, as 5 of 7 patients survived[1 year in our
pilot study with this regimen. Assuming a null hypothesis of
50 % and an alternative hypothesis of 70 % with one-sided
type I error of 0.05 and power of 0.8, with an accrual time of
2 years and follow-up of 1 year after closure of recruitment,
it was necessary to enroll 23 fully assessable patients. The
1-year survival rate was calculated using the Kaplan–Meier
method. Adverse events were graded according to the
National Cancer Institute-Common Terminology criteria




Twelve patients were enrolled in the phase I study between
February 2007 and October 2007 (Table 1). All patients
received at least 2 courses of therapy. ECOG performance
status was 0–1 for all patients. P1 was observed in one
patient, P2 in 6 patients, and P3 in five patients. Two
patients had undergone prior gastrectomy and had also
experienced peritoneal recurrence. Ten patients retained
the primary tumor. One patient had ovarian metastasis and
one patient had liver metastasis. All patients underwent
laparoscopy for diagnosis.
Toxicities
Chemotherapy toxicities per patient during the second
cycle are summarized in Table 2. No patients showed
toxicities of grade 4 or higher, while one patient enrolled
at dose level 3 showed grade 3 neutropenia. At dose
level 4, two experienced grade 3 febrile neutropenia, and
one experienced grade 3 diarrhea. As all three patients
treated at dose level 4 were deemed to have DLT, level 4
was considered as the MTD and level 3 (IP docetaxel
45 mg/m2) was defined as the RD for the ensuing phase
II study.




From November 2007 to October 2010, 27 patients were
enrolled in the phase II study (Table 1): 14 (51.9 %) males
and 13 (48.1 %) females with a median age of 66 years
(range 26–75). All patients had an ECOG performance
status of 0 or 1.
Metastatic sites included the peritoneum (100.0 %),
lymph nodes (22.2 %), liver (7.4 %), and lung (3.7 %), and
22 patients (81.5 %) showed positive peritoneal cytology.
None of the patients included in this study had undergone
prior gastrectomy.
Efficacy
A median of 4 cycles was administered with a range from 2
to 11. Combination chemotherapy was discontinued due to
severe adverse events in two patients and due to disease
progression in 11 patients. Figure 1a shows the overall
survival time after the introduction of this combination
therapy for all patients enrolled in the present study. The
1-year OS rate was 70.4 % (95 % CI 53.2–87.4 %), the
2-year OS rate was 33.4 % (95 % CI 11.8–55.0 %) at a
median follow-up time of 27.6 months, and the MST was
16.2 months (95 % CI 8.4–22.1 months).
After 2 treatment cycles, all 27 patients were evaluated
by second-look laparoscopy or laparotomy. Figure 2 shows
a typical peritoneal tumor response. Before treatment,
numerous metastases were observed on the diaphragm
(panel a), and the peritoneal tumors disappeared macro-
scopically and histologically after treatment (panel b),
which was assessed as CR. Panel d shows residual peri-
toneal tumors less than 50 % of the longest diameter
compared to that before treatment (panel c), which was
assessed as PR.
The peritoneal tumor response rate (RR) and overall RR
were 51.9 % (CR3/PR11/SD10/PD3) and 22 % (CR0/PR6/
SD2/PD3), respectively (Table 3). The 1-year and 2-year
OS rates were 92.8 and 62.5 % for peritoneal responder
group, and 46.1 and 0 % for non-responder group
(Fig. 1b). Cancer cells ceased to be detected by peritoneal
cytology in 18 of 22 (81.8 %) patients.
Surgical treatment
According to the observations of the second-look laparos-
copy, peritoneal responder (n = 14) underwent gastrec-
tomy with lymph node dissection including removal of
peritoneal deposit sites for macroscopic curative resection.
Unfortunately, microscopic residual cancer cells in the
tumor margin (R1 resection) were revealed in 11 of 14
patients. In this study, the tumor margin of residual peri-
toneal deposit site was defined positive, because it was
impossible to remove it with more than 5 mm of sub-per-
itoneal tissue. Among the 14 patients who underwent sur-
gery, postoperative complications occurred in 4 patients
(29 %), anastomotic leakage in one patient, and pancreatic
Table 1 Patients characteristics
Characteristics Phase I Phase II
No. of patients 12 27
Sex
Male 10 (83 %) 14 (49 %)
Female 2 (17 %) 13 (51 %)
Median age in years (range) 63 (33–75) 66 (26–75)
ECOG performance status
0 9 (75 %) 21 (78 %)
1 3 (25 %) 6 (22 %)
Prior treatment
Gastrectomy 2 (17 %) 0 (0 %)
Chemotherapy 0 (0 %) 0 (0 %)
Metastatic organ
Peritoneum 12 (100 %) 27 (100 %)
Peritoneal cytology 11 (92 %) 22 (81 %)
Lymph node 9 (75 %) 6 (22 %)
Liver 1 (8 %) 2 (7 %)
Lung 0 (0 %) 1 (4 %)
Ovary 1 (8 %) 0 (0 %)
PC grade
P1 1 (8 %) 2 (7 %)
P2 6 (50 %) 7 (26 %)
P3 5 (42 %) 18 (67 %)
ECOG Eastern Cooperative Oncology Group, PC Peritoneal
carcinomatosis
Table 2 Toxicities at various dose levels of IP docetaxel plus S-1




35 (n = 3) 40 (n = 3) 45 (n = 3) 50 (n = 3)
G1/2 G3/4 G1/2 G3/4 G1/2 G3/4 G1/2 G3/4
Anemia 2 0 2 0 2 0 0 0
Leukopenia 1 0 0 0 2 0 1 0
Neutropenia 1 0 0 0 1 1 2 0
Thrombocytopenia 0 0 0 0 0 0 0 0
FN – 0 – 0 – 0 – 2
Nausea 2 0 1 0 1 0 3 0
Vomiting 0 0 0 0 0 0 0 0
Diarrhea 1 0 1 0 2 0 1 1
Abdominal pain 1 0 3 0 1 0 2 0
FN Febrile neutropenia
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fistula in 3 patients. No surgery-related mortality (30 days
mortality) was found.
Safety
All patients were assessable for toxicity. Table 4 summa-
rizes chemotherapy toxicity per patient. The incidences of
grade 3/4 hematological and non-hematological toxic
effects were 7.4 and 18.5 %, respectively. The most fre-
quent grade 3/4 toxic effects included neutropenia (7.4 %),
leukopenia (7.4 %), and anorexia (18.5 %). None of the
patients experienced grade 3/4 febrile neutropenia.
Although abdominal pain related to IP infusion was
observed in 5 patients (18.5 %), its severity was less than
grade 2. Infection of the IP access port in one patient was
the only complication related to the peritoneal access
device. There was no chemotherapy-related mortality.
Discussion
We have shown here that IP docetaxel plus S-1 is a highly
active first-line chemotherapy regimen for advanced gastric
cancer with PC.
In the phase I part of this study, we identified IP doce-
taxel at 45 mg/m2 on days 1 and 15 plus S-1 40 mg/m2
twice a day on day 1–14, every 28 days as the recom-
mended treatment schedule for further clinical evaluation.
This dose of IP docetaxel is the same dose as weekly IP
docetaxel, which has already been described as mono-
therapy [18]. During dose escalation, DLT included 2 case
of grade 3 febrile neutropenia and 1 case of grade 3 diar-
rhea during the 2nd cycle. In the present study, the
assessment of DLT was conducted during the first two
cycles, although the conventional phase I study evaluated
toxicities in only the first cycle. This is the reason why
Fig. 1 a Overall survival of all
patients (n = 27) b Overall
survival by peritoneal response.
The solid and dotted lines
present peritoneal responder
(n = 14) and non-responder
(n = 13)
Fig. 2 Examples of
laparoscopic view before and
after treatment. a Numerous
peritoneal tumors on the
diaphragm (before treatment),
b No peritoneal tumor
confirmed histologically (after
treatment), c Peritoneal tumor
on the left lower quadrant
region (before treatment),
d residual peritoneal tumor less
than 50 % of diameter
comparing the tumor in (c)
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patients should generally undergo a second staging lapa-
roscopy after 2 cycles for the confirmation of the treatment
effects on PC.
In the phase II part of this study, our combination reg-
imen showed a 1-year OS rate of 70.4 % (95 % CI
53.2–87.4 %) with MST of 16.2 months (95 % CI
8.4–22.1 months). We obtained satisfactory results which
considered the other phase II or III study for patients with
unresectable or recurrent gastric cancer demonstrated
1-year OS rate around 50 %. Systemic chemotherapy based
on fluorouracil for patients with peritoneal disseminated
gastric cancer showed poorer 1-year OS rate between 20
and 40 %, respectively. Furthermore, cancer cells detected
on peritoneal cytology disappeared in 18 of 22 (82 %)
cases, and the second staging laparoscopy after 2 cycles of
combined chemotherapy showed RR of 52 % and disease
control rate (DCR) of 89 % according to the response
criteria for the treatment of PC.
These superior results were due to the pharmacokinetic
advantage of taxanes after regional delivery [18, 22–24].
Taxanes are absorbed through the openings of lymphatic
system, such as the milky spots and the stomata which are
important sites for the formation of peritoneal dissemina-
tion [25], due to their large molecular weight and fat sol-
ubility. Especially, IP paclitaxel showed a profound
pharmacokinetic advantage 1,000 times higher than sys-
temic administration.
The main problem of IPC is the limited depth of pene-
tration of anticancer drugs directly into the tumor.
Accordingly, optimum use of paclitaxel may consist of
intraperitoneal and intravenous (IV) administration,
because IP paclitaxel reaches the systemic circulation in
only a small amount [26]. Actually, Ishigami et al. [27]
established IP paclitaxel with S-1 plus IV paclitaxel as
systemic chemotherapy, and the results were very
encouraging similar to the present study.
In contrast, docetaxel, one of the taxanes, has a phar-
macokinetic advantage after intraperitoneal delivery which
is hundreds of times higher than systemic administration,
and systemic AUC after IP is twice that after standard IV
docetaxel [18]. These findings indicate that IP docetaxel
has dual anticancer effects via the peritoneal surface and
capillary blood supply. We also described that the mean
value of the peak plasma concentration at 45 mg/m2 of IP
docetaxel was extremely higher than the IC50 value of most
gastric cancer cell lines [18, 28]. Therefore, in using IP
docetaxel, it might be not necessary to perform intravenous
administration as paclitaxel [26].
Fujiwara et al. [29] also reported the usefulness of IP
docetaxel combined with S-1 for gastric cancer with PC. In
a number of previous studies, the estimation of intraperi-
toneal information was unclear to disclose whether only
cancer cell positive on peritoneal cytology or macroscopic
peritoneal metastases exist before treatments. Thus, their
results seem to reflect the high population of positive
peritoneal cytology alone. In the present study, all patients
underwent staging laparoscopy before chemotherapy, and
to enhance the intraperitoneal efficacy, IP docetaxel was
performed twice weekly, which was more frequent than in
previous reports.
In our phase II part, peritoneal responder (n = 14)
underwent surgical treatment. Although most of them were
considered R1 resection, responder showed significant
longer survival than non-responder (p = 0.005).
Table 3 Tumor response
Response No. of patients %











Peritoneal cytology (n = 22)
Turned negative 18 82
Surgical resection (n = 14)
R0 3 21
R1 11 79
Peritoneal tumor was assessed according to the new response criteria
for the treatment against peritoneal carcinomatosis (see Table 1)
NE Not evaluated
Table 4 Toxicity of chemotherapy in phase II (n = 27)
Toxicity (CTCAE v. 3) Grade of adverse events % of grade 3/4
1 2 3 4
Anemia 2 0 0 0 0
Leukopenia 1 2 1 1 7.4
Neutropenia 1 2 1 1 7.4
Thrombocytopenia 0 0 0 0 0
Nausea 3 0 0 0 0
Vomiting 0 0 0 0 0
Diarrhea 1 1 0 0 0
Anorexia 5 2 5 0 18.5
Stomatitis 0 1 0 0 0
Malaise 3 0 0 0 0
Alopecia 2 0 0 0 0
Abdominal pain 4 1 0 0 0
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The most common adverse events in IV docetaxel
combined with S-1 regimen were neutropenia and leuco-
penia, for which the incidences of grade 3/4 were 40–60 %
[21, 30]. In the present study, only 2 patients (7.4 %)
showed grade 3/4 neutropenia and leukopenia due to slow
absorption of docetaxel from the peritoneal cavity in the
systemic circulation. Grade 3 anorexia, however, occurred
in a relatively high proportion of patients (18.5 %). This
may be associated with severe PC in itself because nausea,
which is closely correlated to anorexia, was observed in
three patients with grade 1. As a unique toxic effect of IP
docetaxel, abdominal pain was found in five patients who
required no narcotic analgesia.
Although docetaxel and paclitaxel share major parts of
their structures and mechanisms of action, there is only
partial cross-resistance between these agents [31, 32].
Therefore, each IP taxanes (docetaxel, paclitaxel) may play
a complementary role in case of treatment failure. It will be
interesting to evaluate whether IP docetaxel really acts on
patients who have failed IP paclitaxel.
In conclusion, our study suggested that IP docetaxel plus
S-1 may be a novel treatment option for patients with PC in
gastric cancer. More recently, a retrospective study of
fluoropyrimidine (S-1 or capecitabine) plus cisplatin
showed favorable results in patients with PC [33]. Further
investigations, including controlled clinical trials compar-
ing S-1 plus cisplatin and S-1 plus IP docetaxel used in the
present study, are needed to confirm our findings.
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